- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03722680
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. (RILUZOX-01)
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy: A Phase II Randomized Study by UNICANCER With the Cooperation of AFSOS
It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo.
The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant chemotherapy.
The primary objective is to assess the preventive efficacy of riluzole on the severity of oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy of stage II/III colorectal cancers.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Angers, France
- ICO - Site Paul Papin
-
Beauvais, France
- CH Beauvais
-
Caen, France
- Centre Francois Baclesse
-
Clamart, France
- HIA Percy
-
Clermont-Ferrand, France
- CHU de Clermont -Ferrand
-
Compiègne, France
- Clinique St Côme
-
Creil, France
- GHPSO
-
Dijon, France
- CHU de Dijon
-
Dijon, France
- Centre Georges François Leclerc
-
Pringy, France
- CH Annecy-Genevois
-
Reims, France
- CHU de Reims
-
Reims, France
- Institut Jean Godinot
-
Saint-Herblain, France
- ICO - Site René Gauducheau
-
Saint-Mandé, France
- HIA Begin
-
Saint-Priest, France
- CHU de Saint-Etienne
-
Suresnes, France
- Hôpital Foch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥ 18 years old,
- Eligible patient starting adjuvant oxaliplatin-based chemotherapy (6-12 cycles, Simplified FOLFOX4) for stage II/III colorectal cancer,
- Histological or cytological confirmation of colorectal cancer,
- Performance status (ECOG) ≤2,
- Normal hematological function (ANC ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; hemoglobin ≥9.0 g/dL),
- Normal hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome); aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤3 x ULN, and gamma-glutamyltransferase (GGT) ≤3 x ULN,
- Normal renal function: serum creatinine ≤1.5 x ULN,
- Normal cardiac function: ECG,
- Patients affiliated to the French national health insurance,
- Patient must have signed a written informed consent form prior to any study specific procedures,
- French language comprehension,
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
- Metastatic cancer,
- Diagnosis of neuropathy,
- EORTC QLQ-CIPN20 sensory score >6,
- Previous neurotoxic chemotherapy treatment,
- Patients with chronic obstructive pulmonary disease,
- ALAT/ASAT elevated more than 3 times the normal value,
- Patients with known allergy or severe hypersensitivity to riluzole or any of the study drug excipients,
- Dependence on alcohol or drugs,
- Psychotic disorders,
- Women pregnant or breastfeeding,
- Patients undergoing a measure of legal protection (trusteeship, guardianship ...).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Riluzole
The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval).
The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks).
The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
|
Riluzole during chemotherapy (oxaliplatin)
|
Placebo Comparator: Placebo
Posology, administration and duration of treatment will be equivalent to riluzole group.
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life questionnaire-chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)
Time Frame: 3 months afer initiation of oxaliplatin based chemotherapy (1 cycle = 14 days)
|
QLQ-CIPN20 Questionnaire (EORTC): Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy. The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of chemotherapy-induced peripheral neuropathy (CIPN). Using a 4-point Likert scale (1 = "not at all," 2 = "a little," 3 = "quite a bit," and 4 = "very much"), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms. |
3 months afer initiation of oxaliplatin based chemotherapy (1 cycle = 14 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QLQ-CIPN20
Time Frame: At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Self-reported questionnaire consisting of 20 questions that assess the symptoms and functional limitations of chemotherapy-induced peripheral neuropathy.
The questionnaire is divided in 3 subscales: sensory, motor, and autonomic and gives a comprehensive picture of the nature, frequency, and severity of CIPN.
Using a 4-point Likert scale (1 = "not at all," 2 = "a little," 3 = "quite a bit," and 4 = "very much"), patients indicate the degree to which they have experienced sensory, motor, and autonomic symptoms.
|
At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Time Frame: throughout study completion, assessed up to 43 months
|
The NCI-CTCAE v5.0 is widely accepted in the community of oncology research as the leading rating scale for adverse events.
This scale will assess the severity of sensory neuropathic disorders, this derivative into 5 grades determined by the investigator.
|
throughout study completion, assessed up to 43 months
|
Brief Pain Inventory (BPI) questionnaire
Time Frame: At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
This self-report questionnaire includes:
|
At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Douleur Neuropathique 4 (DN4) questionnaire (interview portion)
Time Frame: This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is ≥4/10.
|
The interview portion of the DN4 questionnaire is a clinician-administered screening tool for neuropathic pain.
The questionnaire includes 7 items, grouped into two questions.
Each item, is answered as either YES or NO.
A final cumulative patient's score is obtained by allocating 1 point for each YES and 0 point for each NO.
If the patient's score is ≥3/7, the test is positive.
|
This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is ≥4/10.
|
Neuropathic Pain Symptom Inventory (NPSI) questionnaire
Time Frame: This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is ≥4/10.
|
This self-reported questionnaire assesses different neuropathic pain symptoms.
The French NPSI includes 12 items that discriminates and quantifies five distinct dimensions of neuropathic pain.
Each of these items are quantified on a (0-10) numerical scale.
|
This evaluation will be carried out only if the item 5 of BPI "general pain felt in the last 7 days" is ≥4/10.
|
QLQ-C30 questionnaire (EORTC)
Time Frame: At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
This self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Disease progression
Time Frame: From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months.
|
Disease Free Survival, defined as the interval between the date of randomization and the date of cancer relapse (local, regional, metastases, second cancer) or death from any cause, whichever occurs first.
|
From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months.
|
Time to HRQoL score deterioration
Time Frame: At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
The interval between randomization and deterioration ≥5 points in the HRQoL score as compared to baseline score or death (all causes).
|
At inclusion (V0), 3 months (V2), up to 7 months (V3), up to 9 months (V4), up to 12 months (V5), up to 15 months (V6), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Quantification of chemotherapy dose reductions
Time Frame: 3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
The number of chemotherapy dose reduction caused by severe neuropathy and/or poor tolerance of treatment will be recorded.
|
3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
Quantification of cumulative dose
Time Frame: 3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
The cumulative dose (mg/m²) of chemotherapy delivered to patients will be recorded.
|
3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
Evaluation of study exit rates
Time Frame: 3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
The study exit rate caused by severe neuropathy and/or poor tolerance of treatment will be recorded.
|
3 months (V2) and up to 7 months (V3) after initiation of oxaliplatin based chemotherapy.
|
Assessment of glutamate serum level
Time Frame: Glutamate serum level will be dose at inclusion (V0), 3 months (V2), up to 7 months (V3), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Correlation with colorectal cancer tumors/nodes/metastases (TNM) score (and eventually neuropathic symptoms), glutamate plasmatic
|
Glutamate serum level will be dose at inclusion (V0), 3 months (V2), up to 7 months (V3), and up to 18 months (V7) after initiation of oxaliplatin based chemotherapy.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Neuroprotective Agents
- Protective Agents
- Anticonvulsants
- Riluzole
Other Study ID Numbers
- UC-0106/1712
- 2017-002320-25 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oxaliplatin-induced Peripheral Neuropathy
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingOxaliplatin Induced Peripheral Neuropathy in Cancer PatientsBangladesh
-
Chang Gung Memorial HospitalUnknownChemotherapy | Oxaliplatin-induced Peripheral NeuropathyTaiwan
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
University Health Network, TorontoRecruitingChemotherapy-induced Peripheral NeuropathyCanada
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
WinSanTor, IncRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Veloxis PharmaceuticalsRecruitingChemotherapy-induced Peripheral NeuropathyUnited States, Japan
-
National University Hospital, SingaporePaxman Coolers Ltd.; The N.1 Institute for Health, National University of SingaporeRecruitingChemotherapy-induced Peripheral NeuropathySingapore
Clinical Trials on Placebo Oral Tablet
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
The Mind Research NetworkTerminatedSmoking Cessation | Tobacco Use DisorderUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis CChina
-
Cara Therapeutics, Inc.TerminatedChronic Kidney Diseases | PruritusUnited States